Research progress of endothelial injury in the development of graft-versus-host disease

doi:10.16352/j.issn.1001-6325.2023.11.1728

Abstract

Abstract: Graft-versus-host disease (GVHD) is one of the most serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), resulting a very high mortality risk and no effective diagnosis and treatment method. Although an increasing number of studies suggest that immune-mediated vascular endothelial damage plays an important role in GVHD, the specific mechanism remains elusive. On the basis of endothelial injury caused by radiotherapy and chemotherapy before allo-HSCT and infection, the donor T cells directly contact with the damaged endothelial cell antigen, secrete cytokines and inflammatory mediators to kill endothelial cells, leading to further apoptosis and depletion of endothelial cells, and exacerbating the functional damage of target organs and multi-system injury of the body. To explore the endothelial injury mechanism of GVHD. This review provides a new idea for the prevention and treatment of GVHD.

Key words: allogeneic hematopoietic stem cell transplantation, graft-versus-host disease, endothelial injury

CLC Number:

R392.4

LU Wenqi, WAN Lin. Research progress of endothelial injury in the development of graft-versus-host disease[J]. Basic & Clinical Medicine, 2023, 43(11): 1728-1732.

References 25

[1]	McDonald GB, Sandmaier BM, Mielcarek M, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003—2007 versus 2013—2017 cohorts[J]. Ann Intern Med, 2020, 172:229-239.
[2]	Haji S, Shiratsuchi M, Takamatsu A, et al. Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation[J]. Int J Hematol, 2023, 117:438-445.
[3]	Boittin FX, Beddek K, Thery H, et al. The immunosuppressant drug cyclosporin A aggravates irradiation effects in endothelial cells[J]. Biochem Biophys Res Commun, 2022, 602:127-134.
[4]	Mulder K, Patel AA, Kong WT, et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease[J]. Immunity, 2021, 54:1883-1900.
[5]	Yalcin K, Pehlivan B, Celen S, et al. Comparison of total Body irradiation-based versus chemotherapy-based conditionings for early complications of allogeneic hematopoietic stem cell transplantation in children with ALL[J]. J Pediatr Hematol Oncol, 2021, 43:266-270.
[6]	Link-Rachner CS, Sockel K, Schuetz C. Established and emerging treatments of skin GvHD[J]. Frontiers Immunol Vol, 2022,13:838494.doi:10.3389/fimmu.2022.838494.
[7]	Deschaumes C, Verneuil L, Ertault-Daneshpouy M, et al. CD95 ligand-dependant endothelial cell death initiates oral mucosa damage in a murine model of acute graft versus host disease[J]. Lab Invest, 2007, 87: 417-429.
[8]	Zouali H, Lemasson J, Calugareanu A, et al. RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea[J]. Blood Adv, 2022, 6:2805-2811.
[9]	Lopes PDD, de Assis N, de Araújo NF, et al. COX/iNOS dependence for angiotensin-Ⅱ-induced endothelial dysfunction[J]. Peptides, 2022, 157:170863. doi:10.1016/j.peptides.2022.170863.
[10]	Ogasawara R, Hashimoto D, Kimura S, et al. Intestinal lymphatic endothelial cells produce R-spondin3[J]. Sci Rep, 2018, 8: 10719. doi:10.1038/s41598-018-29100-7.
[11]	Mertlitz S, Shi Y, Kalupa M, et al. Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition pro-tects against experimental GVHD[J]. Blood, 2017, 129: 1865-1875.
[12]	Gloude NJ, Khandelwal P, Luebbering N, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD[J]. Blood, 2017, 130: 1259-1266.
[13]	Qi J, Pan T, You T. Upregulation of HIF-1α contributes to complement activation in transplantation-associated thrombotic microangiopathy[J]. Br J Haematol, 2022, 199: 603-615.
[14]	Özkan HA, Özkan SG. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: diagnosis, incidence, prophylaxis, and treatment[J]. Transfus Apher Sci, 2022, 61:103372. doi: 10.1016/j.transci.2022.103372.
[15]	Pereira M, Lee NT, Noonan J. Early endothelial activa-tion in a mouse model of graft vs host disease following chemotherapy[J]. Front Immunol, 2021, 12: 708554. doi: 10.3389/fimmu.2021.708554.
[16]	Cordes S, Mokhtari Z, Bartosova M. Endothelial damage and dysfunction in acute graft-versus-host disease[J]. Haematologica, 2021, 106: 2147-2160.
[17]	Gavriilaki E, Sakellari I, Anyfanti P, et al. Assessment of endothelial injury and pro-coagulant activity using circulating microvesicles in survivors of allogeneic hematopoietic cell transplantation[J]. Int J Mol Sci, 2020, 21:9768. doi:10.3390/ijms21249768.
[18]	Mathew NR, Vinnakota JM, Apostolova P, et al. Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia[J]. J Clin Invest, 2020, 130: 1315-1329.
[19]	Bonelli F, Lasagni Vitar RM, Merlo Pich FG, et al. Corneal endothelial cell reduction and increased neurokinin-1 receptor expression in a graft-versus-host disease preclini-cal model[J]. Exp Eye Res, 2022, 220:109128. doi:10.1016/j.exer.2022.109128.
[20]	Ranjan S, Goihl A, Kohli S, et al. Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells[J]. Nat Commun, 2017, 8:311. doi:10.1038/s41467-017-00169-4.
[21]	Dorrance AM, Moutuou MM, Goda C, et al. Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice[J]. Blood Adv, 2022, 6: 2403-2408.
[22]	García-Bernal D, Palomo M, Martínez CM, et al. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease[J]. J Cell Mol Med, 2020, 24: 8031-8044.
[23]	Zhao K, Tian Y, Wang J, et al. Fluvastatin-pretreated donor cells attenuated murine aGVHD by balancing effector T cell distribution and function under the regula-tion of KLF2[J]. Biomed Res Int, 2020, 2020:7619849. doi:10.1155/2020/7619849.
[24]	Bézie S, Charreau B, Vimond N, et al. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice[J]. Blood Adv, 2019, 3: 3522-3538.
[25]	Wang W, Ye Y, Du Y, et al. EPC infusion ameliorates acute graft-versus-host disease-related endothelial injury after allogeneic bone marrow transplantation[J]. Front Immunol, 2022, 13:1019657. doi:10.3389/fimmu.2022.1019657.